Tucatinib NEW

Description:

Tucatinib is an oral medication that is classified as a tyrosine kinase inhibitor. It is primarily used in the treatment of certain types of breast cancer, specifically those that are human epidermal growth factor receptor 2-positive (HER2-positive).

Key Information and Uses:

Indication:

HER2-Positive Breast Cancer: Tucatinib is indicated for the treatment of adult patients with metastatic HER2-positive breast cancer, particularly in those who have received one or more prior anti-HER2 therapies. It is often used in combination with other medications, such as trastuzumab and capecitabine.

Mechanism of Action:

Tucatinib selectively inhibits the activity of the HER2 protein, which is overexpressed in certain breast cancers. By blocking HER2 signaling pathways, Tucatinib helps to slow down or stop the growth of cancer cells that rely on this protein for proliferation and survival.

Administration:

Tucatinib is taken orally, typically twice daily. It can be taken with or without food, but patients should follow their healthcare provider's specific instructions regarding dosage and administration.

Side Effects:

Common side effects of Tucatinib may include diarrhea, nausea, fatigue, liver enzyme elevations, and rash. Patients should be monitored for these side effects, and any significant changes should be reported to a healthcare provider.

Clinical Trials:

Tucatinib has been evaluated in clinical trials, including the HER2CLIMB study, which demonstrated its efficacy in improving progression-free survival in patients with HER2-positive breast cancer, particularly in those with brain metastases.

Approval:

Tucatinib received approval from the U.S. Food and Drug Administration (FDA) for use in combination with other therapies for the treatment of metastatic HER2-positive breast cancer, marking an important advancement in targeted cancer therapy.